Novo Sees Brighter China Outlook As Volumes Rise
Novo Nordisk says its China business is regaining strength, helped by improved volumes and broad growth in the diabetes sector and despite pricing pressures, and sees a brighter outlook ahead of the local approval of Tresiba.
You may also be interested in...
If 2016's Year of the Monkey was a period of ups and downs in China, filled with a series of rapid changes in regulations and plans for overseas expansion by domestic pharma companies, 2017's Year of the Rooster is likely to be even more uncertain, industry insiders say.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.